1-7 of 7
Robert P. Numerof
Close
Sort by
Journal Articles

An Observational Study of Fostamatinib As Second Line Therapy in Adult Patients with Immune Thrombocytopenia (ITP) in Real-World Clinical Practice

David Hughes, Robert P. Numerof, Andrea Zider, Donna Chow, Ruchika Goel
Journal: Blood
Blood (2021) 138 (Supplement 1): 4223.
https://doi.org/10.1182/blood-2021-153144
Published: 2021
Journal Articles

Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Sandra Tong, MD, Robert P. Numerof, PhD, Jane Datangel, RN, Esteban Masuda, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-140907
Published: 2020
Journal Articles

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Nichola Cooper, MD, Robert P. Numerof, PhD, Sandra Tong, MD, David J. Kuter, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-140469
Published: 2020
Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter
Journal: Blood
Blood (2019) 134 (Supplement_1): 4800.
https://doi.org/10.1182/blood-2019-126544
Published: 2019
Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter
Journal: Blood
Blood (2019) 134 (Supplement_1): 3518.
https://doi.org/10.1182/blood-2019-126509
Published: 2019
Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4889.
https://doi.org/10.1182/blood-2019-126558
Published: 2019
Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1069.
https://doi.org/10.1182/blood-2019-126473
Published: 2019